Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rotacaps are a specialized dry powder inhalation (DPI) formulation consisting of medication-filled capsules designed for use with a dry powder inhaler, such as the Rotahaler. Developed originally by GlaxoSmithKline (GSK) and widely produced by manufacturers like Cipla, Rotacaps provide a pre-metered dose of respiratory medication. The active ingredients within Rotacaps vary depending on the specific product; common versions include bronchodilators like salbutamol (e.g., Ventolin or Asthalin Rotacaps) for rapid relief of bronchospasm, and inhaled corticosteroids like beclometasone (e.g., Beclate Rotacaps) for long-term inflammation control in asthma and chronic obstructive pulmonary disease (COPD). The mechanism involves the mechanical opening or piercing of the capsule within the device, allowing the patient to inhale the dry powder—often mixed with a lactose carrier—directly into the bronchial tree. This delivery method is particularly advantageous for patients who struggle with the hand-breath coordination required for traditional pressurized metered-dose inhalers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rotacaps.